Home PROTAC Molecule Bcl-xL/PROTAC
The Bcl-2 family of proteins, exemplified by Bcl-xL and Bcl-2, plays pivotal roles in promoting cancer cell survival. The structural analysis of Bcl-xL laid the groundwork for the development of the initial inhibitors targeting the Bcl-2 family, leading to FDA-approved drugs. Recently, the concept of Proteolysis Targeting Chimeras (PROTACs) that induce the degradation of Bcl-xL has emerged as a therapeutic approach, aiming to enhance efficacy and reduce toxicity compared to traditional antagonists. However, as of now, no ternary complex structures involving Bcl-xL, a PROTAC, and an E3 ligase have been successfully determined to guide this innovative strategy.
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :